Biotechnology News

– Study met its primary endpoint, with afimetoran demonstrating higher SRI-4 response rates versus placebo at Week 48 (p-value <0.001 across all dose groups) – – Secondary endpoints demonstrated...

Allogenetics Raises €3.8 Million Pre-Series A to Advance Novel Ex Vivo Gene Therapy Approach to Improve Organ Transplantation Outcomes

Innovate UK grant supports Athernal’s mission to intercept high-risk leukaemia before cancer developsFunding reflects growing confidence in cancer interception as an emerging therapeutic approach  ...

ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury

GENFIT highlights the long-term commercial opportunity associated with NIS4® and next-generation NIS2+®

Un test sanguin simple, fiable et déployable à grande échelle permettrait d’identifier les patients atteints de MASH à risque parmi les près de 90 millions d’Américains bénéficiant d’un suivi médical...

SHENZHEN, China, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The 21st Annual Meeting of the International Conference on Genomics (ICG-21) was held at the BGI Center in Shenzhen from September 7 to 8. Under...

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4,...

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a...

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly...